Glenn Sblendorio - Mar 30, 2022 Form 4 Insider Report for IVERIC bio, Inc. (ISEE)

Signature
/s/ Todd Anderman, as Attorney-in-Fact for Glenn P. Sblendorio
Stock symbol
ISEE
Transactions as of
Mar 30, 2022
Transactions value $
-$630,179
Form type
4
Date filed
4/1/2022, 07:03 PM
Previous filing
Mar 29, 2022
Next filing
Apr 6, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ISEE Common Stock Options Exercise $3.57K +1.21K +0.43% $2.94 281K Mar 30, 2022 Direct F1
transaction ISEE Common Stock Sale -$20.6K -1.21K -0.43% $17.00 280K Mar 30, 2022 Direct F1, F2
transaction ISEE Common Stock Options Exercise $4.12K +1.4K +0.5% $2.94 281K Mar 31, 2022 Direct F1
transaction ISEE Common Stock Sale -$23.8K -1.4K -0.5% $17.02 280K Mar 31, 2022 Direct F1, F3
transaction ISEE Common Stock Options Exercise $120K +40.8K +14.57% $2.94 320K Apr 1, 2022 Direct F1
transaction ISEE Common Stock Sale -$713K -40.8K -12.72% $17.50 280K Apr 1, 2022 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ISEE Stock Option (right to buy) Options Exercise $0 -1.21K -0.33% $0.00 367K Mar 30, 2022 Common Stock 1.21K $2.94 Direct F1, F5
transaction ISEE Stock Option (right to buy) Options Exercise $0 -1.4K -0.38% $0.00 366K Mar 31, 2022 Common Stock 1.4K $2.94 Direct F1, F5
transaction ISEE Stock Option (right to buy) Options Exercise $0 -40.8K -11.14% $0.00 325K Apr 1, 2022 Common Stock 40.8K $2.94 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021, and as described in the Registrant's Proxy Statement for its 2022 Annual Meeting of the Stockholders, as filed with the Securities and Exchange Commission on March 30, 2022.
F2 The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $17.00 to $17.01 per share on March 30, 2022. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range.
F3 The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $17.00 to $17.02 per share on March 31, 2022. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range.
F4 The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $17.00 to $17.83 per share on April 1, 2022. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range.
F5 This stock option award was granted on December 19, 2017 and vested with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date.